Dexcom stock outlook lifts as record 2026 patient growth seen
Published on 11/19/2026 at 02:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth and coverage outlook
- DexCom expects a record number of new patients in 2026, with US growth led by Type 2 diabetes users.
- Management expects a CMS decision on broader Medicare coverage before the end of 2026.
- DexCom targets more than 10 percent annual revenue growth through 2030 and operating margins of 29 to 30 percent.
DexCom expects a record number of new patients in 2026 and has lifted its outlook to the top end of the range set at the start of the year, executives said in a Jefferies discussion reported by MarketBeat on Wednesday, November 18. US growth is being driven mainly by people with Type 2 diabetes who use insulin and by commercially insured users who do not.
Dexcom stock was quoted at 74.40 euros on Frankfurt at 8:10 a.m. CET on Wednesday, November 18. The company news gives investors a fresh focus on patient additions, reimbursement access and the pace at which new coverage could translate into demand.
Medicare decision remains ahead
DexCom is awaiting a decision from the Centers for Medicare and Medicaid Services on broader coverage for people with Type 2 diabetes. Chief Executive Jake Leach said a decision is expected before year-end, while reimbursement could reach patients around mid-2027 if the process advances as planned.
The expansion has not been approved. DexCom is using results from its CONNECT study to support broader access, while management continues to assess pricing and product-mix pressures. The company also expects its G7 15 Day sensor rollout to support US market-share gains.
Long-term targets and capital allocation
Chief Financial Officer and Chief Operating Officer Jereme Sylvain said DexCom's plan through 2030 calls for annual revenue growth above 10 percent. The plan also targets gross margins in the high 60 percent range and operating margins of 29 to 30 percent, compared with an operating margin of 24 percent in 2026 according to the report.
DexCom plans another 1 billion US dollars in share buybacks in 2027 and has committed to returning at least half of growing free cash flow to shareholders. The company also plans to launch Dexcom Direct in January 2027 to help patients and physicians navigate insurance and reimbursement.
Business model and market position
Dexcom develops glucose biosensing technology and continuous glucose monitoring systems for people with diabetes. Its portfolio includes the G6 and G7 systems, connected software and services, and Stelo, an over-the-counter biosensor for adults who do not use insulin. The company serves users and caregivers through wearable sensors, receivers and mobile-device connections, with international expansion identified as a major long-term opportunity.
DexCom company facts
- Company: DexCom, Inc.
- ISIN: US2521311074
- Ticker: DXCM
- Home exchange: Nasdaq
- Frankfurt quote: 74.40 euros on Wednesday, November 18, 2026, at 8:10 a.m. CET
- Business: Continuous glucose monitoring and glucose biosensing technology
The S&P 500 provides the broader US market context for healthcare and technology shares.
More news and analyses on Dexcom stock are available in the company coverage.
